The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preferences for treatment to delay bone metastases (BM) in patients with castration-resistant prostate cancer (CRPC) at high risk of developing BM.
Yi Qian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
A. Brett Hauber
Research Funding - Amgen
Juan Marcos Gonzalez
Research Funding - Amgen
Joshua Posner
Research Funding - Amgen
Ateesha F Mohamed
No relevant relationships to disclose
Bertrand Tombal
Consultant or Advisory Role - Amgen; Astellas Pharma; Bayer; Ferring; Medivation; Sanofi
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Medivation; Sanofi
Research Funding - Amgen; Astellas Pharma; Bayer; Ferring; Medivation; Sanofi
Expert Testimony - Amgen; Dendreon
Jean-Jacques Body
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Novartis
Francesca Gatta
Employment or Leadership Position - Amgen
Jorge Arellano
Employment or Leadership Position - Amgen
Stock Ownership - Amgen